RecruitingPhase 1NCT07639047

An Initial Evaluation of AN8025 in Solid Tumors

Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of AN8025 in Participants With Unresectable Advanced or Metastatic Solid Tumors

Sponsor

Adlai Nortye Biopharma Co., Ltd.

Enrollment

91 participants

Start Date

Nov 1, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor (Phase 1)

Summary

The goal of this clinical trial is to determine the appropriate dose of AN8025 for use in the treatment of advanced solid tumors. This study will be conducted in in adults \>18 years of age. The main questions to answer: 1. Determine which dose level of AN8025 is safe and tolerability in participants with advanced solid tumors 2. To determine the maximum tolerated of AN8025 for future testing. Participants will visit their study site in 3 week cycles, during which they will be under go treatment with AN8025 and visit their clinical site during each cycle for check ups and testing.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AN8025 is a multifunctional antibody fusion protein for people with advanced solid tumor (phase 1). The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.